Increase in stockholder equity and note extension strengthen Company’s ability to advance pancreatic cancer development strategy (Form 8-K)

Increase in stockholder equity and note extension strengthen Company's ability to advance pancreatic cancer development strategy

OCALA, Fla., May 19, 2026 / AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced a significant increase in stockholder equity and that the Company has entered into Amendment #2 to its existing promissory note agreement with Streeterville Capital, LLC, extending the maturity date to June 30, 2027.

AIM recently reported stockholder equity of approximately $2.1 million as of March 31, 2026, which is a significant increase of approximately $11.9 million in stockholder equity from the reported stockholder deficit of approximately $9.8 million as of December 31, 2025. The Company has also raised equity-generating funds through various transactions since March 31, 2026.

The Company believes the increase in stockholder equity and the note extension further support its ability to prudently manage capital resources while maintaining focus on near-term milestones, including continued advancement of its pancreatic cancer development program and other strategic initiatives intended to maximize long-term stockholder value.

"We appreciate the continued support and confidence demonstrated by Streeterville Capital through this extension," said AIM Chief Executive Officer Thomas Equels. "This amendment enhances our capital allocation flexibility at an important stage for the Company as we remain focused on executing our clinical and operational priorities. We believe the coming quarters present multiple potential catalysts that could create meaningful stockholder value and further expand our strategic optionality."

Under the terms of the amendment, the maturity date of the promissory note originally issued on February 16, 2024, has been extended from its prior maturity to June 30, 2027. Following the amendment and associated extension fee, the outstanding balance of the note is approximately $1.68 million.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.